![](/files/Doctor/profile/prof_2745_20210510135841.png)
![Dr Angela George](/files/Doctor/profile/prof_2745_20210510135841.png)
Dr Angela George areas of expertise:
Professional statement
Dr Angela George is a consultant medical oncologist in gynaecology and practices at the Royal Marsden Hospital in Chelsea, London. She attends to both private and NHS referrals at her clinic, specialising in treatment of gynaecological cancers such as ovarian and endometrial with a particular focus on the use of genomic information in treatment.
Her specialist knowledge surrounding genomic profiling and use of mutational information and inherited cancer syndromes assists Dr George in guiding her treatment at the Royal Marsden Hospital, where she is also clinical director of genomics. Furthermore, her oncogenetics practice takes in testing for inherited cancer syndromes.
Dr George began her training in medical oncology in New Zealand, moved to the Royal Marsden Hospital and undertook additional training in oncogenetics at the Institute of Cancer in London. It was here where she was awarded the Chairman's Prize for her thesis in ovarian cancer genetics.
Her genomics expertise saw her implement the Mainstreaming Cancer Genetics programme, which ran from 2013-2018. Her work has been adopted across the UK and across the world. The programme involved the introduction of genetic testing into the routine care of patients with ovarian, breast and pancreatic cancers and the current programmes have expanded into multiple tumour types.
Further to her industry-leading work, Dr George is the Cancer Clinical Lead of the North London Genomic Medicine Service and co-chairs the molecular tumour board. She also is involved in the National Cancer Research Institute gynaecological cancers group, the Precision Medicine working group for the European Society of Medical Oncology and the British Society of Genetic Medicine (BSGM). Dr George is the principal investigator at The Royal Marsden for multiple international trials and her research, particularly in cancer genomics and targeted treatments, has featured widely in various books and peer-reviewed publications.